In add-on studies, it is recommended that patients completing double-blind assessment be offered indefinite open-label treatment, and that safety data be collected prospectively.
However, given the impossibility of double-blind assessment of open placebo versus no-treatment control, the effects of report bias cannot be eliminated.
Mean MSQ and Medical Outcome Study Short Form 36 (SF-36) change scores (baseline to each double-blind assessment point) were calculated for pooled intent-to-treat (ITT) patients.
After two weeks, patients returned for the first double-blind assessments (visit 3).
Of the remaining 300, an additional 4 withdrew from the study before completing any double-blind assessments, for a total of 296 patients in the mITT population.
Although tDCS has been suggested as a therapeutic tool for many cognitive and neurological impairments, very few tDCS studies have conducted double-blind assessments in either clinical or non-clinical populations.
Details of the individual studies, including the baseline characteristics of patients are shown in additional file 2 and outcome results are shown in additional file 3. Most trials provided an efficacy analysis based on the 'all patients treated approach' meaning that patients with at least one baseline assessment and one double blind on-treatment assessment were included.
To be included in the primary analysis, the trial design had to be double blind and the assessment of falls sufficiently specified according to the following criteria: (a) falls had to be a primary or secondary end point defined at the onset of the trial; (b) the study had to include a definition of falls and how they were assessed; and (c) falls had to be assessed for the entire trial period.
However, methodological differences and in some cases, a lack of more severe scientific criteria (such as double blind protocols) hinder the assessment of the effectiveness of these vaccines.
Even within the 14 high dose trials, variation between trials was larger than expected, supporting our pre-defined strategy of focusing on fall efficacy from double blind trials with sufficient fall assessment.
Station 4: Objective (double blinded) real-time assessment of hand hygiene technique with a purpose built imaging device.
